Patient selection for magnetic resonance imaging of prostate cancer

European Urology

Volumn 40, Issue 3, 2001, Pages 300-307

  Engelbrecht, Marc R ^a   Jager, Gerrit J ^a   Severens, J L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Magnetic resonance imaging; Prostate cancer; Threshold approach

Indexed keywords

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; DECISION TREES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0035742157     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049790     Document Type: Article

References (32)

1. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
2. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
3. Current trends in prostate cancer diagnosis and staging among United States urologists
4. Therapeutic decision making: A cost-benefit analysis
5. The threshold approach to clinical decision making
6. Benefits and costs of MR imaging of prostate cancer
7. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer
8. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer
9. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer
10. Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma
11. Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate
12. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
13. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
14. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml
15. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels
16. Ability of sextant biopsies to predict radical prostatectomy stage
17. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer
18. Problems in selecting the adequate patient population from existing data files for assessment studies of new diagnostic tests
19. Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer
20. Risk factors for complications and morbidity after radical retropubic prostatectomy
21. Cost-efficient radical prostatectomy with a clinical care path
22. Modelling in health economic evaluation: What is its place? What is its value?
23. Prostate cancer staging: Should MR imaging be used? A decision analytic approach
24. Local staging of prostate carcinoma with endorectal coil MRI: Correlation with whole-mount radical prostatectomy specimens
25. A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation
26. Local staging of prostatic carcinoma: Comparison of transrectal sonography and endorectal MR imaging
27. Präoperatives T-staging des prostatakarzinoms: Endorektale magnetresonanztomographie im vergleich zu anderen bildgebenden und klinischen methoden
28. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
29. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
30. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? IV. Estimating the risks and benefits of an early detection program